

GlaxoSmithKline (Ireland) Limited 12 Riverwalk Citywest Business Campus Dublin D24 YK11 Ireland

T +353 1 495 5000

		2024 Patient Organisa	tion ToV disclosure and methodological note for GSK (Ire	ומחמן גנמ		
PO name	Country	Types of the support	Description of the	Monetary value of financial	Non-monetary	Fees for service
	,	or services provided	support or services 1	support and of invoiced costs	benefit for PO 2	paid
ACET Ireland	Ireland	Financial support	Project grant of €14,300 to support the Positive Youth Project.	€ 14,300.00		
Alpha-1 Foundation	Ireland	Financial support	Project grant of €1,500 to support the annual National Alpha-1 Patient Conference 2024.	€ 1,500.00		
ARC Cancer support	Ireland	Financial support	Project grant of ξ 10,000 was given to support of Child Counselling Services & Manual Lymph Drainage Therapy in 2024. Project grant of ξ 8,100 to support the establishment of a gynaecological cancer support group.	€ 18,100.00		
Clare Cancer Support	Ireland	Financial support	Project grant of €18,450 to support World Ovarian Cancer Day 2024 activities.	€ 18,450.00		
COPD Support Ireland	Ireland	Financial support	Project grant of €35,000 to support World Health Day & World COPD Day 2024 national awareness campaigns.	€ 35,000.00		
HIV Ireland	Ireland	Financial support	Project grant of €5,000 to support the 2024 Red Ball.	€ 5,000.00		
Marie Keating Foundation	Ireland	Financial support	Project grant of €10,000 to support the 2024 Survive & Thrive Programme.	£ 10,000.00		
Ovacare	Ireland	Financial support	Project grant of €8,500 to support World Gynaecological Oncology Day 2024 activities.	€ 8,500.00		
Sexual Health West	Ireland	Financial support	Project grant of €12,000 to support the development of testing and disability services in 2024.	€ 12,000.00		
	Ireland	Financial support	Project grant of €3,000 to support the 2024 Media Monitoring project.	€ 3,000.00		
		Significant indirect support		In euros		
		Non-financial support			In euros	
	UK-registered charity so disclosed by GlaxoSmithKline UK				€ 1.009.58	In euros

Summary of methodology used by GlaxoSmithKline (Ireland) Limited in preparing the 2024 report on Transfers of Value to Patient Organisations in Ireland.

GlaxoSmithKline (Ireland) Limited works with Patient Organisations that:

Have the interests of patients at the core of their mission. Are credible, independent, and legitimate with official or legal status.

Have patients and/or carers/caregivers on the board. Have robust governance processes such as a constitution, bylaws, or audits.

Are transparent about funding, with an annual report or equivalent official documentation. Are not for profit.

Transfers of Value (ToV): Financial support and/or significant indirect/non-financial support and/or payment for contracted services provided by GlaxoSmithKline (Ireland) Limited to a Patient Organisation:

The monetary value of financial support. The non-monetary benefit that the PO receives when the non-financial support cannot be assigned to a meaningful monetary value.

Reporting period: This report covers payments and non-monetary support provided during the 2024 calendar year.

Preparation of disclosure report:

Information on projects with and support of patient organisations is taken from the records of our patient organisation oversight committee. These data are compiled into an annual report, reviewed, approved and disclosed on our website: https://www.gsk.com/en-gb/contact-us/worldwide/ireland/

Registered in Ireland No. 15513 Registered Office: 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland

Directors: E.A. Caslin, I.M. McCarron, G.S. Whelan.

GlaxoSmithKline (Ireland) Limited a private company limited by shares.

Date of Preparation: May 2025 NP-IE-NA-COCO-250001